The inhibition of the STAT3 pathway in both cancer and immune cells (particularly myeloid populations) constitutes an important target for cancer therapy, including MM therapy [19–22, 24, 25, 31–35]. This evidence concerns the gene STAT3 and Miyoshi myopathy.